The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors.
Saved in:
| Title: | The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. |
|---|---|
| Authors: | Gueble SE; Department of Therapeutic Radiology, Yale School of Medicine, P.O. Box 208040, HRT 134, New Haven, CT, 06520-8040, USA., Vasquez JC; Department of Pediatrics, Yale School of Medicine, New Haven, CT, 06520, USA., Bindra RS; Department of Therapeutic Radiology, Yale School of Medicine, P.O. Box 208040, HRT 134, New Haven, CT, 06520-8040, USA. ranjit.bindra@yale.edu.; Department of Pathology, Yale School of Medicine, New Haven, CT, 06520, USA. ranjit.bindra@yale.edu. |
| Source: | Current treatment options in oncology [Curr Treat Options Oncol] 2022 Nov; Vol. 23 (11), pp. 1566-1589. Date of Electronic Publication: 2022 Oct 15. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Current Science, Inc Country of Publication: United States NLM ID: 100900946 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6277 (Electronic) Linking ISSN: 15346277 NLM ISO Abbreviation: Curr Treat Options Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
